Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the combination of osimertinib and carotuximab to
assess the safety and find the recommended dose for treatment of advanced EGFR-mutated
non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of
dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for
Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary
objectives include evaluating the rate of objective response rate, duration of response,
progression-free survival, and disease control rate, along with assessing biomarkers through
tumor tissue and circulating tumor DNA.